Roquefort Therapeutics plc (LON:ROQ)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.9500
-0.0500 (-5.00%)
Mar 26, 2026, 5:15 PM GMT
Market Cap1.51M -55.6%
Revenue (ttm)n/a
Net Income-882.45K
EPS-0.06
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume507,197
Average Volume142,108
Open1.0600
Previous Close1.0000
Day's Range0.9500 - 1.0600
52-Week Range0.9500 - 30.0000
Beta-0.56
RSI46.22
Earnings DateApr 27, 2026

About Roquefort Therapeutics

As of March 27, 2026, Roquefort Therapeutics plc (LSE:ROQ) was acquired by Coiled Therapeutics Inc. in a reverse merger transaction. Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gen... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 7
Stock Exchange London Stock Exchange
Ticker Symbol ROQ
Full Company Profile

Financial Performance

Financial Statements